Skip to main content

and
  1. Article

    Open Access

    Patient Perceptions Regarding Multiple Myeloma and Its Treatment: Qualitative Evidence from Interviews with Patients in the United Kingdom, France, and Germany

    The current standard of care for multiple myeloma requires several regimens of treatment, with patients experiencing high symptom burden and side effects, which negatively impact health-related quality of life...

    Jianming He, Ashley Duenas, Hannah Collacott in The Patient - Patient-Centered Outcomes Re… (2021)

  2. Article

    Open Access

    Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial

    In the phase III ALCYONE trial, daratumumab plus bortezomib/melphalan/prednisone (D-VMP) significantly improved overall response rate and progression-free status compared with VMP alone in transplant-ineligibl...

    Stefan Knop, Maria-Victoria Mateos, Meletios A. Dimopoulos, Kenshi Suzuki in BMC Cancer (2021)

  3. Article

    Open Access

    Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study

    The phase 3 COLUMBA study demonstrated noninferiority of subcutaneous daratumumab (DARA SC) to intravenous daratumumab (DARA IV) in relapsed or refractory multiple myeloma. We present a subgroup analysis of As...

    Shinsuke Iida, Takayuki Ishikawa, Chang Ki Min, Kihyun Kim in Annals of Hematology (2021)

  4. No Access

    Article

    Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results

    The phase III COLUMBA study evaluated daratumumab (DARA) intravenous (IV) and subcutaneous (SC) in patients with relapsed or refractory multiple myeloma. Here, we report patient-reported satisfaction with ther...

    Saad Z. Usmani, Maria-Victoria Mateos in Journal of Cancer Research and Clinical On… (2021)

  5. Article

    Open Access

    Symptom burden and health-related quality of life impacts of smoldering multiple myeloma: the patient perspective

    Smoldering multiple myeloma (SMM) is an early form of multiple myeloma (MM). SMM is typically considered asymptomatic, and research on how it affects health-related quality of life (HRQoL) is limited. This stu...

    Milenka Jean-Baptiste, Katharine S. Gries in Journal of Patient-Reported Outcomes (2020)

  6. Article

    Open Access

    Using a digital patient powered research network to identify outcomes of importance to patients with multiple myeloma

    Social media platforms give patients a voice by allowing them to discuss their health and connect with others. These unfiltered and genuine reports offer direct access to what matters most to patients. Explori...

    Katharine S. Gries, John Fastenau in Journal of Patient-Reported Outcomes (2020)

  7. No Access

    Article

    Comprehensive validation of the functional assessment of anorexia/cachexia therapy (FAACT) anorexia/cachexia subscale (A/CS) in lung cancer patients with involuntary weight loss

    Comprehensive (qualitative and quantitative) assessments of the 12-item functional assessment of anorexia/cachexia therapy (FAACT) anorexia/cachexia subscale (A/CS) and relevant subscales were undertaken for u...

    Heather L. Gelhorn, Katharine S. Gries, Rebecca M. Speck in Quality of Life Research (2019)

  8. Article

    Open Access

    Response scale selection in adult pain measures: results from a literature review

    The purpose of this literature review was to examine the existing patient-reported outcome measurement literature to understand the empirical evidence supporting response scale selection in pain measurement fo...

    Shima Safikhani, Katharine S. Gries in Journal of Patient-Reported Outcomes (2018)

  9. Article

    Open Access

    Literature review to characterize the empirical basis for response scale selection in pediatric populations

    Despite the importance of response option selection for patient-reported outcome measures, there seems to be little empirical evidence for the selected scale type. This article provides an overview of the publ...

    April N. Naegeli, Jennifer Hanlon in Journal of Patient-Reported Outcomes (2018)

  10. No Access

    Article

    Utility Estimates of Disease-Specific Health States in Prostate Cancer from Three Different Perspectives

    To develop a statistical model generating utility estimates for prostate cancer specific health states, using preference weights derived from the perspectives of prostate cancer patients, men at risk for prost...

    Katharine S. Gries, Dean A. Regier in Applied Health Economics and Health Policy (2017)

  11. No Access

    Article

    Current Status and Trends in Performance-Based Risk-Sharing Arrangements Between Healthcare Payers and Medical Product Manufacturers

    Our objective was to identify and characterize publicly available cases and related trends for performance-based risk-sharing arrangements (PBRSAs). We performed a review of PBRSAs over the past 20 years (1993...

    Josh J. Carlson, Katharine S. Gries in Applied Health Economics and Health Policy (2014)

  12. No Access

    Article

    Psychometric evaluation of the National Eye Institute Visual Function Questionnaire and Visual Function Questionnaire Utility Index in patients with non-infectious intermediate and posterior uveitis

    To evaluate the psychometric properties of the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) and Visual Function Questionnaire Utility Index (VFQ-UI) in patients with non-infectious inte...

    Rupali K. Naik, Katharine S. Gries, Anne M. Rentz in Quality of Life Research (2013)

  13. Article

    Open Access

    Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence

    Treatment options for overactive bladder (OAB) with urinary urge incontinence (UUI) refractory to oral antimuscarinics include: botulinum toxin type A (BoNTA), sacral neuromodulation (SNM), and augmentation cy...

    Jonathan D Campbell, Katharine S Gries, Jonathan H Watanabe, Arliene Ravelo in BMC Urology (2009)